An update of the etiology and management of xerostomia.

Salivary gland disease gives rise to salivary gland enlargement, pain, and prolonged xerostomia (dry mouth). Xerostomia is the most common long-standing problem for the majority of affected patients. There are many causes of dry mouth, with long-standing xerostomia being a particular problem in Sjögren's syndrome and after radiation to the head and neck region. Xerostomia is usually managed with saliva substitutes, but a large number of potential systemic therapies of long-standing xerostomia now exist. Some-particularly immunosuppressants-are of fundamental interest for the potential reduction of gland damage in Sjögren's syndrome but as yet are of limited clinical usefulness. Others, particularly pilocarpine and cevimeline, are, or have the potential to be, clinically useful in stimulating salivation by virtue of their action on cholinergic receptors.

[1]  J. L. Jensen,et al.  Salivary gland involvement in hypohidrotic ectodermal dysplasia. , 2008, Oral diseases.

[2]  L. M. Lehman,et al.  A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. , 1995, The New England journal of medicine.

[3]  K. Yoneda,et al.  Treatment of xerostomia with the bile secretion-stimulating drug anethole trithione: a clinical trial. , 1999, The American journal of the medical sciences.

[4]  A. Soto-Rojas,et al.  The oral side of Sjögren syndrome. Diagnosis and treatment. A review. , 2002, Archives of medical research.

[5]  A. Kao,et al.  Impaired salivary function in patients with noninsulin-dependent diabetes mellitus with xerostomia. , 2002, Journal of diabetes and its complications.

[6]  G. Lodi,et al.  Oral involvement in chronic graft-vs-host disease following allogenic bone marrow transplantation. , 2002, Archives of dermatology.

[7]  J. Montastruc,et al.  A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs , 1997, European Journal of Clinical Pharmacology.

[8]  I. Mackay,et al.  Epstein-Barr virus as an etiological agent in primary Sjögren's syndrome. , 1987, Medical hypotheses.

[9]  James K. Ellis,et al.  Induction Paclitaxel, Carboplatin, and Infusional 5‐FU Followed by Concurrent Radiation Therapy and Weekly Paclitaxel/Carboplatin in the Treatment of Locally Advanced Head and Neck Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network , 2002, Cancer journal.

[10]  Yoshiya Tanaka,et al.  A PRELIMINARY STUDY ON THE INTERFERON-α TREATMENT FOR XEROSTOMIA OF SJÖGREN'S SYNDROME , 1993 .

[11]  C. Avellini,et al.  Chronic lymphocytic sialoadenitis in HCV‐related chronic liver disease: comparison with Sjögren's syndrome , 1997, Histopathology.

[12]  J. Epstein,et al.  A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study. , 1994, Oral surgery, oral medicine, and oral pathology.

[13]  M. A. Criswell,et al.  Hyperthermic, Supersaturated Humidification in the Treatment of Xerostomia , 2001, The Laryngoscope.

[14]  E. Tindall,et al.  Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. , 2002, Archives of internal medicine.

[15]  B. J. Baum,et al.  Salivary enhancement: current status and future therapies. , 2001, Journal of dental education.

[16]  R. Fox,et al.  Update in Sjögren syndrome. , 2000, Current opinion in rheumatology.

[17]  A. Cooke,et al.  Pilocarpine as Antagonist to the Undesired Effects of Ganglion-blocking Agents in Treatment of Hypertension , 1954, British medical journal.

[18]  R. Fox,et al.  Approaches to the treatment of Sjögren's syndrome. , 2000, The Journal of rheumatology. Supplement.

[19]  C. Scully,et al.  Adverse drug reactions in the mouth. , 2000, Clinics in dermatology.

[20]  A. Nagler,et al.  The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. , 2001, Archives of oral biology.

[21]  J. Büntzel,et al.  Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. , 2002, Seminars in radiation oncology.

[22]  B. Ferguson Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer , 1994 .

[23]  F. Howell,et al.  Treatment of primary Sjögren's syndrome with hydroxychloroquine. , 1988, The American journal of medicine.

[24]  Jensen,et al.  Pretreatment symptoms and dosing regimen predict side‐effects of interferon therapy for hepatitis C , 2000, Journal of viral hepatitis.

[25]  I. M. Sheppard Oral Manifestations of Diabetes Mellitus: A Study of One Hundred Cases , 1942 .

[26]  T. Daniels,et al.  The cilical effects of electrostimulation on salivary function of Sjögren's syndrome patients , 1992, Rheumatology International.

[27]  G. R. Davies,et al.  An investigation into the use of pilocarpine as a sialagogue in patients with radiation induced xerostomia. , 2002, Australian dental journal.

[28]  C. Scully,et al.  HIV topic update: protease inhibitor therapy and oral health care. , 2008, Oral diseases.

[29]  A. Vissink,et al.  Prevention and treatment of the consequences of head and neck radiotherapy. , 2003, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[30]  D. Schuller,et al.  Determination of the Efficacy of Topical Oral Pilocarpine for Postirradiation Xerostomia in Patients With Head and Neck Carcinoma , 1996, The Laryngoscope.

[31]  S. Yamazaki,et al.  Sarcoidosis with giant parotomegaly. , 2001, Cutis.

[32]  R. Riffenburgh,et al.  Acupuncture for xerostomia: clinical update , 2001 .

[33]  I. Mackay,et al.  Primary Sjögren's syndrome after infectious mononucleosis. , 1985, Annals of internal medicine.

[34]  L. Niskanen,et al.  Saliva in non-insulin-dependent diabetic patients and control subjects: The role of the autonomic nervous system. , 1998, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[35]  P. Fox,et al.  Prednisone and piroxicam for treatment of primary Sjögren's syndrome. , 1993, Clinical and experimental rheumatology.

[36]  J. Esteban,et al.  Immunohistochemistry of minor salivary gland biopsy specimens from patients with Sjögren’s syndrome with and without hepatitis C virus infection , 1997, Annals of the rheumatic diseases.

[37]  W. Jackson,et al.  Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). , 1991, Archives of internal medicine.

[38]  R. Jonsson,et al.  Current issues in Sjögren's syndrome. , 2002, Oral diseases.

[39]  T. Suzuki,et al.  Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis. , 1994, The Journal of rheumatology.

[40]  H. S. Davis,et al.  A Controlled Study , 1966 .

[41]  M. Blom,et al.  The effect of acupuncture on salivary flow rates in patients with xerostomia. , 1992, Oral surgery, oral medicine, and oral pathology.

[42]  N. Rhodus,et al.  Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome. , 2000, The Journal of otolaryngology.

[43]  O. Cameron,et al.  Pilocarpine for anticholinergic adverse effects associated with desipramine treatment. , 1996, American Journal of Psychiatry.

[44]  M. Rowe,et al.  Sjögren's syndrome after infection by Epstein-Barr virus. , 1990, Journal of Rheumatology.

[45]  Gerald. D. Levy,et al.  Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. , 1997, Arthritis and rheumatism.

[46]  D. Allalouf,et al.  Clinical trial of bromhexine in Sjögren's syndrome. , 1981, Annals of ophthalmology.

[47]  A. Ravindran,et al.  A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. , 1997, The Journal of clinical psychiatry.

[48]  J. Hamburger Sjögren's syndrome as seen by an oral physician , 2001, Scandinavian journal of rheumatology. Supplement.

[49]  Finn Ls,et al.  What the mouth has to say about diabetes. Careful examinations can avert serious complications. , 1997 .

[50]  D. Menon,et al.  Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[51]  T. Lundeberg,et al.  The effect of acupuncture in the treatment of patients with primary Sjögren's syndrome. A controlled study. , 1998, Acta odontologica Scandinavica.

[52]  C. Scully,et al.  Oral health care for the cancer patient. , 1996, European journal of cancer. Part B, Oral oncology.

[53]  N. Kline,et al.  Pilocarpine With Psychostimulants , 1965 .

[54]  Y. Iga,et al.  (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. , 1998, Japanese journal of pharmacology.

[55]  J. Epstein,et al.  A clinical comparative trial of saliva substitutes in radiation-induced salivary gland hypofunction. , 1992, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

[56]  Everett Hc The use of bethanechol chloride with tricyclic antidepressants. , 1975 .

[57]  H. C. Everett The use of bethanechol chloride with tricyclic antidepressants. , 1975, The American journal of psychiatry.

[58]  Y. Takeda,et al.  Sicca symptom in a patient with hemochromatosis: minor salivary gland biopsy for differential diagnosis. , 1987, International journal of oral and maxillofacial surgery.

[59]  S. Bowman,et al.  Collaborative research into outcome measures in Sjögren's syndrome , 2002, Scandinavian journal of rheumatology. Supplement.

[60]  P. Hooper,et al.  The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study. , 1997, British journal of urology.

[61]  P. Vescovi,et al.  Update on diabetes mellitus and related oral diseases. , 2004, Oral diseases.

[62]  C. Scully,et al.  HIV: the surgeon's perspective. Part 3. Diagnosis and management of malignant neoplasms. , 1994, The British journal of oral & maxillofacial surgery.

[63]  B. Walker,et al.  Hepatitis C virus infection. , 2001, The New England journal of medicine.

[64]  B. Iranpour,et al.  Alteration in parotid salivary flow in diabetes mellitus. , 1970, Oral surgery, oral medicine, and oral pathology.

[65]  E. Bruera,et al.  Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain , 1999, Supportive Care in Cancer.

[66]  S. Buckley Lacrimal and salivary secretion in Sjogren's syndrome: The effect of systemic treatment with bromhexine , 1985 .

[67]  T. Daniels,et al.  Effectiveness of pilocarpine in postradiation xerostomia , 1987, Cancer.

[68]  P. Strang,et al.  Acupuncture for Patients in Hospital-Based Home Care Suffering from Xerostomia , 1999, Journal of palliative care.

[69]  M. Mravak-Stipetić,et al.  Xerostomia in patients with triple A syndrome – a newly recognised finding , 2000, European Journal of Pediatrics.

[70]  K. Sullivan,et al.  Pilocarpine for radiation-induced xerostomia in head and neck cancer. , 2000, International journal of palliative nursing.

[71]  R. Fox,et al.  Sjögren's syndrome: mechanisms ofpathogenesis involve interaction of immune and neurosecretory systems , 2002, Scandinavian journal of rheumatology. Supplement.

[72]  R. Fox,et al.  Sjögren's syndrome , 1995, The Lancet.

[73]  J. Epstein,et al.  Synergistic effect of sialagogues in management of xerostomia after radiation therapy. , 1987, Oral surgery, oral medicine, and oral pathology.

[74]  C. Scully,et al.  Parotid salivary secretion in diabetic autonomic neuropathy. , 1991, The Journal of diabetic complications.

[75]  J. Prutting PILOCARPINE NITRATE AND PSYCHOSTIMULANTS. ANTAGONISTIC AGENT TO ANTICHOLINERGIC EFFECTS. , 1965, JAMA.

[76]  P. Fox,et al.  Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction , 1993, Cancer.

[77]  D. Schubert Use of bethanechol chloride with phenothiazines: a case report. , 1979, American Journal of Psychiatry.

[78]  A. Hill,et al.  Evening primrose oil and borage oil in rheumatologic conditions. , 2000, The American journal of clinical nutrition.

[79]  Yoshiyuki Suzuki,et al.  Serum levels of γ-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection , 2003 .

[80]  A. van der Heide,et al.  Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. , 1993, Annals of the rheumatic diseases.

[81]  S. Miyawaki,et al.  Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. , 1999, Internal medicine.

[82]  R. Manthorpe,et al.  Effects of mouthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjögren's syndrome. A double-blind crossover investigation. , 2001, Gerodontology.

[83]  A. B. Richards,et al.  Treatment of primary Sjogren's syndrome with low-dose natural human interferon-α administered by the oral mucosal route: A phase II clinical trial , 1999 .

[84]  D. Isenberg,et al.  Sjögren's syndrome: a critical review of clinical management. , 2000, The Journal of rheumatology.

[85]  P. Voulgari,et al.  Sicca syndrome in patients with sarcoidosis , 1999, Rheumatology International.

[86]  R. Yee,et al.  Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjögren's syndrome. The MGI PHARMA Sjögren's Syndrome Study Group. , 1998, Advances in experimental medicine and biology.

[87]  W. Bowen,et al.  Periodontal health, dental caries, and metabolic control in insulin-dependent diabetic children and adolescents. , 1987, Pediatric dentistry.

[88]  K. Shiozawa,et al.  A preliminary study on the interferon-alpha treatment for xerostomia of Sjögren's syndrome. , 1993, British journal of rheumatology.

[89]  G. Sadler,et al.  Managing the oral sequelae of cancer therapy. , 2003, Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses.

[90]  M. Cohen,et al.  Salivary composition in diabetic patients. , 1988, The Journal of diabetic complications.

[91]  S. Arimori,et al.  Clinical trial of Ambroxol in Sjogren's syndrome , 1988 .

[92]  J. Horiot,et al.  Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[93]  P. Terasaki,et al.  Association of Sjögren's syndrome with HLA-B8. , 1976, Arthritis and rheumatism.

[94]  H. Moutsopoulos,et al.  Antimalarials in Sjögren's syndrome--the Greek experience. , 1996, Lupus.

[95]  E. Pow,et al.  Salivary gland function and xerostomia in southern Chinese following radiotherapy for nasopharyngeal carcinoma , 2003, Clinical Oral Investigations.

[96]  Y. Ukai,et al.  Chronic anethole trithione treatment enhances the salivary secretion and increases the muscarinic acetylcholine receptors in the rat submaxillary gland. , 1984, Archives internationales de pharmacodynamie et de therapie.

[97]  L. V. D. van de Putte,et al.  Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjögren's syndrome , 2001, Annals of the rheumatic diseases.

[98]  S. Grafakos,et al.  The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients. , 2001, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[99]  R. Morton,et al.  Quality of life and nutritional studies in Sjogren's syndrome patients with xerostomia. , 2001, The New Zealand dental journal.

[100]  B. Angmar-Månsson,et al.  Acupuncture treatment of patients with radiation-induced xerostomia. , 1996, European journal of cancer. Part B, Oral oncology.

[101]  S. Singhal,et al.  Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. , 1997, Leukemia & lymphoma.

[102]  M. Yaron,et al.  Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers , 1999, Annals of the rheumatic diseases.

[103]  G. Sharp,et al.  Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease , 1996, Lupus.

[104]  S. Wei,et al.  Chewing gum and saliva in oral health. , 1997, The Journal of clinical dentistry.

[105]  F. Labrousse,et al.  Prevalence and characteristics of Sjögren's syndrome or Sicca syndrome in chronic hepatitis C virus infection: a prospective study. , 2001, The Journal of rheumatology.

[106]  A. Davies A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer , 2000, Palliative medicine.

[107]  M. Erlichman Patient selection criteria for electrostimulation of salivary production in the treatment of xerostomia secondary to Sjogren's syndrome. , 1990, Health technology assessment reports.

[108]  J. Saurat,et al.  The lichen planus like and sclerotic phases of the graft versus host disease in man: an ultrastructural study of six cases. , 1981, Acta dermato-venereologica.

[109]  R. Balon Bupropion and nightmares. , 1996, The American journal of psychiatry.

[110]  C. Jenkins,et al.  Effects of antihypertensive medications on quality of life in elderly hypertensive women. , 1994, American journal of hypertension.

[111]  C. Scully,et al.  Lack of association between hepatitis C virus and Sjogren's syndrome. , 2008 .

[112]  R. Müller,et al.  Radiation-induced hyposalivation and its treatment with oral pilocarpine. , 1998, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[113]  C. Scully,et al.  Oral complications of cancer therapies: prevention and management. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

[114]  A. Masumoto,et al.  Development of Sjögren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C , 1996, Journal of Gastroenterology.

[115]  P. Fox,et al.  Use of orally administered anhydrous crystalline maltose for relief of dry mouth. , 2001, Journal of alternative and complementary medicine.

[116]  T. Lundeberg,et al.  Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. , 2008, Oral diseases.

[117]  B. Vikram,et al.  Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  T. Appelboom,et al.  Zidovudine in primary Sjögren's syndrome. , 1999, Rheumatology.

[119]  Schubert Ds Use of bethanechol chloride with phenothiazines: a case report. , 1979 .

[120]  N. Rhodus,et al.  Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride: a pilot study. , 1998, Quintessence international.

[121]  D. B. Ferguson The flow rate and composition of human labial gland saliva. , 1999, Archives of oral biology.

[122]  C. Ekdahl,et al.  Health-related quality of life in primary Sjögren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36 , 2000, Scandinavian journal of rheumatology.

[123]  R. Bartrons,et al.  Fluoride and pilocarpine reduce the risk of caries produced by chronic clomipramine treatment in rats. , 1997, Caries Research.

[124]  C. Scully,et al.  Management of xerostomia. , 1992, Journal.

[125]  J. Zacny,et al.  Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers , 2000, Psychopharmacology.

[126]  Salah Rs,et al.  Pilocarpine for anticholinergic adverse effects associated with desipramine treatment. , 1996 .

[127]  J. Groopman,et al.  Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[128]  A. Rubinow,et al.  The use of oral pilocarpine in xerostomia and Sjögren's syndrome. , 1999, Seminars in arthritis and rheumatism.

[129]  K. Sullivan,et al.  Oral manifestations of chronic graft-v-host disease. , 1984, Archives of internal medicine.

[130]  G. Krishnaswamy,et al.  Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[131]  J. Epstein,et al.  Effects of compliance with fluoride gel application on caries and caries risk in patients after radiation therapy for head and neck cancer. , 1996, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[132]  R. Fox,et al.  Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study , 1996 .

[133]  K. Eguchi,et al.  Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjögren’s syndrome , 1998, Annals of the rheumatic diseases.

[134]  R. Weiss,et al.  Human retrovirus-5 proviral DNA is rarely detected in salivary gland biopsy tissues from patients with Sjögren's syndrome. , 1997, Arthritis and rheumatism.

[135]  M. Schiødt,et al.  Treatment of xerostomia in patients with primary Sjögren's syndrome with sulfarlem. , 1986, Scandinavian journal of rheumatology. Supplement.

[136]  N. Ogawa,et al.  Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. , 2002, Arthritis and rheumatism.

[137]  F. Vivino,et al.  Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. , 1999, Archives of internal medicine.

[138]  J. Vincelj,et al.  Pilocarpine in the prevention of postirradiation xerostomia. , 2000, Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti.

[139]  S. Challacombe,et al.  Patient preferences in a preliminary study comparing an intra-oral lubricating device with the usual dry mouth lubricating methods , 2002, British Dental Journal.

[140]  M. Schiødt,et al.  HIV-associated salivary gland disease: a review. , 1992, Oral surgery, oral medicine, and oral pathology.

[141]  C. Scully,et al.  Orofacial effects of antiretroviral therapies. , 2001, Oral diseases.

[142]  D. Greenspan,et al.  Xerostomia associated with didanosine , 1992, The Lancet.

[143]  D. Horrobin Essential fatty acid and prostaglandin metabolism in Sjögren's syndrome, systemic sclerosis and rheumatoid arthritis. , 1986, Scandinavian journal of rheumatology. Supplement.

[144]  A. Nagler,et al.  Parotid salivary gland dysfunction in chronic graft-versus-host disease (cGVHD): a longitudinal study in a mouse model , 2000, Bone Marrow Transplantation.

[145]  P. Venables,et al.  A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. , 1998, The Journal of rheumatology.

[146]  R. Fox,et al.  Sjögren’s syndrome: current therapies remain inadequate for a common disease , 2000, Expert opinion on investigational drugs.

[147]  W. S. Wilson,et al.  The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. , 1995, Archives of oral biology.

[148]  Rees Td The diabetic dental patient. , 1994, Dental clinics of North America.

[149]  W. H. Hall Oral complications of cancer therapies. , 1990, Journal of neurosurgery.

[150]  T. Masuhara,et al.  Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome. , 1994, General pharmacology.

[151]  I. Katayama,et al.  Oral Prednisolone Improved Acetylcholine-Induced Sweating in Sjögren's Syndrome-Related Anhidrosis , 2000, Clinical Rheumatology.

[152]  R. P. Thompson,et al.  Omeprazole and dry mouth. , 1995, Scandinavian journal of gastroenterology.

[153]  L. Vrielinck,et al.  Sicca syndrome with iron deposition in the salivary glands. , 1988, International journal of oral and maxillofacial surgery.

[154]  H. Joensuu,et al.  Pilocarpine and carbacholine in treatment of radiation-induced xerostomia. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[155]  C. Aromdee,et al.  A pilot study of the disposition of pilocarpine in plasma, saliva and urine after a single oral dose. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[156]  J. Hamilton-miller,et al.  A pilot study of Salix SST (saliva-stimulating lozenges) in post-irradiation xerostomia. , 1998, Current medical research and opinion.

[157]  S. Arimori,et al.  Clinical trial of ambroxol (Mucosolvan) in Sjögren's syndrome. , 1988, The Tokai journal of experimental and clinical medicine.

[158]  S. E. Taylor,et al.  Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[159]  D. Bataille,et al.  Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. , 1993, Arthritis and rheumatism.

[160]  D. Samarawickrama Saliva substitutes: how effective and safe are they? , 2002, Oral diseases.

[161]  S. Singhal,et al.  Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease. , 1995, Blood.

[162]  J. Bergdahl,et al.  Low Unstimulated Salivary Flow and Subjective Oral Dryness: Association with Medication, Anxiety, Depression, and Stress , 2000, Journal of dental research.

[163]  N. Rhodus Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome. , 2008, Oral diseases.

[164]  L. Sreebny,et al.  Xerostomia in Diabetes Mellitus , 1992, Diabetes Care.

[165]  E. Bruera,et al.  Potential novel uses of thalidomide: focus on palliative care. , 2000, Drugs.

[166]  J. M. González-Campoy,et al.  What the mouth has to say about diabetes. Careful examinations can avert serious complications. , 1997, Postgraduate medicine.

[167]  C. Bucca,et al.  Respiratory function in systemic lupus erythematosus: relation with activity and severity , 1996, Lupus.

[168]  T. Nederfors Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists. , 1996, Swedish dental journal. Supplement.

[169]  J. Schornagel,et al.  Quality-of-life assessment after supradose selective intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable stage IV head and neck squamous cell carcinoma. , 2002, Archives of otolaryngology--head & neck surgery.

[170]  S. Porter,et al.  The investigation of major salivary gland agenesis: a case report. , 2001, Pediatric dentistry.

[171]  A. Pedersen,et al.  LongoVital in the treatment of Sjögren's syndrome. , 1999, Clinical and experimental rheumatology.

[172]  A. Pedersen,et al.  Primary Sjögren’s syndrome: oral aspects on pathogenesis, diagnostic criteria, clinical features and approaches for therapy , 2001, Expert opinion on pharmacotherapy.

[173]  F. Salaffi,et al.  Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. , 1996, Clinical and experimental rheumatology.

[174]  G. Wall,et al.  Pharmacotherapy of Xerostomia in Primary Sjögren's Syndrome , 2002, Pharmacotherapy.

[175]  A. Davies,et al.  A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer , 1998, Palliative medicine.

[176]  F. Vivino The treatment of Sjögren's syndrome patients with Pilocarpine-tablets , 2001, Scandinavian journal of rheumatology. Supplement.

[177]  I. Al-Hashimi,et al.  A new medication for treatment of dry mouth in Sjögren's syndrome. , 2001, Texas dental journal.

[178]  C. Vitali Classification criteria for Sjögren’s syndrome , 2003, Annals of the rheumatic diseases.

[179]  L. Henderson,et al.  Oral health of patients with hepatitis C virus infection: a pilot study. , 2001, Oral diseases.

[180]  C. Scully,et al.  Hepatitis C virus infection: Review and implications for the dentist. , 1998, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[181]  N. Rhodus,et al.  s-IgA and cytokine levels in whole saliva of Sjögren's syndrome patients before and after oral pilocarpine hydrochloride administration: a pilot study , 1998, Clinical Oral Investigations.

[182]  R. Sulkava,et al.  Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. , 2001, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[183]  H. Moutsopoulos,et al.  Methotrexate in primary Sjögren's syndrome. , 1996, Clinical and experimental rheumatology.

[184]  S. Nagataki,et al.  High prevalence of Sjögren’s syndrome in patients with HTLV-I associated myelopathy , 1997, Annals of the rheumatic diseases.

[185]  C. Scully,et al.  Synergism between HIV and other viruses in the mouth. , 2002, The Lancet. Infectious diseases.

[186]  D. Horrobin,et al.  Patients with primary Sjögren's syndrome treated for two months with evening primrose oil. , 1986, Scandinavian journal of rheumatology.

[187]  P. D. Dios,et al.  Whole stimulated salivary flow in patients with chronic hepatitis C virus infection. , 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[188]  S. Rogers,et al.  Health-related quality of life in patients with primary Sjögren's syndrome and xerostomia: a comparative study. , 2002, Gerodontology.

[189]  A. Nagler,et al.  Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study , 1999, Bone Marrow Transplantation.

[190]  Stanley B. Cohen,et al.  A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. , 2002, Arthritis and rheumatism.

[191]  M. Rowley,et al.  Antimitochondrial autoantibodies in saliva and sera from patients with primary biliary cirrhosis , 2001, Journal of gastroenterology and hepatology.

[192]  M. Ferguson Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction. , 1993, Oral surgery, oral medicine, and oral pathology.

[193]  J. Rieke,et al.  A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  G. Carlson,et al.  The salivary glands. Embryology, anatomy, and surgical applications. , 2000, The Surgical clinics of North America.

[195]  A. Nagler,et al.  Histopathological study of the human submandibular gland in graft versus host disease. , 1999, Journal of clinical pathology.

[196]  J. Schoenberger,et al.  Self-reported side effects from antihypertensive drugs. A clinical trial. Quality of Life Research Group. , 1990, American journal of hypertension.

[197]  K. Shiozawa,et al.  Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[198]  T. Ogasawara,et al.  Enhancement of salivary secretion by chronic anethole trithione treatment. , 1988, Archives internationales de pharmacodynamie et de therapie.

[199]  M. Takeyama,et al.  Enhancement of salivary secretion and neuropeptide (substance P, α‐calcitonin gene‐related peptide) levels in saliva by chronic anethole trithione treatment , 2001, The Journal of pharmacy and pharmacology.

[200]  明 塩沢 口腔乾燥症状改善薬 塩酸セビメリン水和物(サリグレン®カプセル30 mg)の薬理学的特性と臨床効果 , 2002 .

[201]  D. Beighton,et al.  Xerostomia in patients with advanced cancer. , 2001, Journal of pain and symptom management.

[202]  T. Appelboom,et al.  Infliximab in primary Sjögren's syndrome: one-year followup. , 2002, Arthritis and rheumatism.

[203]  R. Cowan,et al.  Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia? , 1999, European Journal of Nuclear Medicine.

[204]  J. Epstein,et al.  A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. , 1999, Oral oncology.

[205]  R. Riffenburgh,et al.  Acupuncture for xerostomia , 2002, Cancer.

[206]  T. Rees The diabetic dental patient. , 1994, Dental clinics of North America.

[207]  C. Jacobs,et al.  A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. , 1996, Oncology.

[208]  R. Jonsson,et al.  Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome. , 2000, Scandinavian journal of rheumatology.

[209]  P. Johnstone,et al.  Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. , 2001, International journal of radiation oncology, biology, physics.

[210]  Fei Liu,et al.  A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer , 2000, Supportive Care in Cancer.

[211]  M I Koukourakis,et al.  Amifostine in clinical oncology: current use and future applications , 2002, Anti-cancer drugs.

[212]  Y. Ukai,et al.  Enhancement of Phosphatidylinositol Turnover and Cyclic Nucleotide Accumulation by Chronic Anethole Trithione Treatment in Rat Submaxillary Glands , 1989, The Journal of pharmacy and pharmacology.

[213]  C. del Rio,et al.  Diagnosis of diffuse CD8+ lymphocytosis syndrome in HIV-infected patients. , 2002, The AIDS reader.

[214]  J. Connell,et al.  Hydrallazine-induced Sjögren's syndrome. , 1988, International journal of oral and maxillofacial surgery.

[215]  G. Lockwood,et al.  A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.

[216]  F. Momm,et al.  Treatment of xerostomia following radiotherapy: does age matter? , 2002, Supportive Care in Cancer.